CARDIZEM (diltiazem hydrochloride) by Ichnos Glenmark Innovation is clinical pharmacology the therapeutic effects of diltiazem are believed to be related to its ability to inhibit the cellular influx of calcium ions during membrane depolarization of cardiac and vascular smooth muscle. Approved for hypertension, chronic stable angina, angina due to coronary artery spasm. First approved in 1991.
Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
CARDIZEM (diltiazem hydrochloride) is a calcium channel antagonist administered via injection for acute management of cardiac arrhythmias and hypertensive episodes. It treats hypertension, chronic stable angina, and angina due to coronary artery spasm by inhibiting calcium influx into cardiac and vascular smooth muscle cells, reducing heart rate, blood pressure, and myocardial oxygen demand.
With LOE approaching and minimal Part D spending ($224K in 2023), the CARDIZEM brand team is likely a small, maintenance-focused group managing a mature injectable cardiovascular agent.
CLINICAL PHARMACOLOGY The therapeutic effects of diltiazem are believed to be related to its ability to inhibit the cellular influx of calcium ions during membrane depolarization of cardiac and vascular smooth muscle. Mechanisms of Action Hypertension: Diltiazem produces its antihypertensive effect…
Worked on CARDIZEM at Ichnos Glenmark Innovation? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moCARDIZEM offers limited career advancement potential given its LOE-approaching lifecycle and minimal commercial activity. Roles available are primarily defensive and cost-containment focused, suited for professionals seeking stability over growth.